Thomas Yip: Understood. And then perhaps switching gears both — 3Q and CF, we see that for Phase 1 studies are ongoing. When should we expect data from these studies?
Joseph Payne: For the CF study?
Thomas Yip: Yeah.
Joseph Payne: Yeah. See the Phase 1b study, we’ve guided some in-term Phase 1b data in the first half of next year. With respect to the Phase 1 study, we’ve now informed the market that we intend to provide a presentation at an appropriate conference in the first half of next year as well.
Thomas Yip: Understood. Just one last question from us. This one is probably for Andy. The 35 million milestone received from CSL, can you discuss what was the trigger events for the milestone?
Andrew Sassine: Yeah. The milestone was related to our COVID in the bivalent program. So hopefully that will help answer that question. And then you — been able to articulate the progress we’re having with the bivalent study in Japan, and we’re very encouraged by the speed and success of that trial moving quite rapidly. Thank you.
Thomas Yip: Understood. Thank you again for taking my questions.
Andrew Sassine: Thank you.
Operator: The next question comes from Yale Jen with Laidlaw and Company. Please proceed.
Yale Jen: Good evening, and thanks for taking the question. I just switch gears to the flu vaccine that to be started soon. My question is that given CSL is a major player in this space and recently, some of the other messenger RNA flu vaccine has probably had some issues, maybe on the safety or and efficacy. So what — both you guys and CSL think that how would your messenger of RNA vaccine could potentially to overcome some of those hurdles and actually have a better product.
Padmanabh Chivukula: Yeah. Conventional messenger RNA flu vaccines have potential challenges relating to better dose-related challenges and also durability challenges and that’s where self-amplifying mRNA this next-generation technology can prove to be different and good base that we could — because the dose is much lower. There may be some additional flexibilities there with respect to multivalency and including different antigens. But and also what we’ve shown in the recent data in our infectious disease vaccine trials is that this next-generation self-amplifying mRNA technology is more durable and that is especially important in the flu shots space or the flu vaccine space. So those would be areas of differentiation.
Yale Jen: Okay, great. That’s very helpful. And maybe one more question here, which is for the bivalent COVID vaccine. Once they potentially approved in Japan, what is the commercial strategy outside of Japan been contemplated? And was there something also in the United States as well? Thanks.
Padmanabh Chivukula: Right now, all the regulatory is interested in monovalent vaccines, and not necessarily bivalent vaccines. So if that does, we’re in a position provide whatever the customer wants, whether that’s an updated bivalent technology or monovalent.
Yale Jen: Okay, great. Thanks a lot. Appreciate it.
Padmanabh Chivukula: Yeah. Thank you, Yale.
Operator: Thank you. At this time, I would like to turn the call back over to Mr. Payne for closing remarks.
Joseph Payne: Yeah. Thanks everyone for participating on the call. If there is any remaining questions, don’t hesitate to reach out the team and we’ll get back to you as soon as we can. Thanks to everyone and good night.
Operator: Thank you. This does concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation and have a great day.
